Previous studies have indicated that in STAD, the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and HMCN1 co-mutation significantly reduced patient mortality risk. Here, HMCN1 is linked to gastric adenocarcinoma.